AC Immune’s experimental imaging agent ACI-19626 continues to show a good safety profile and has shown promise for detecting toxic TDP-43 protein clumps in people with amyotrophic lateral sclerosis ...
She was a woman of faith and told me her mantra was a quote from medieval mystic Julian of Norwich: “All shall be well, and all shall be well, and all manner of thing shall be well.” But things were ...
The APOE4 gene variant influences the spread of toxic TDP-43 protein clumps in ALS. APOE4 carriers are more likely to have ...
Gauthier begins, “My father could use a little mercy now.” In that first verse, she sings that the fruits of his labor fall and rot slowly on the ground. “His work is almost over/ It won’t be long and ...
Outsee received an award to use AI for discovering new ALS treatments. The company's Nomaly platform will analyze genomic data from 9,000 ALS patients. The goal is to identify new therapeutic targets ...
A study showed cholesterol-lowering statins do not significantly affect ALS progression or survival. Statin prescriptions for ALS patients should be based on metabolic needs, not ALS diagnosis. More ...
Differences in the inflammatory activity of certain immune cells may explain why amyotrophic lateral sclerosis (ALS) progresses faster in some people than others, according to a study. The findings ...
Neurizon received approval for a Phase 1 trial of liquid NUZ-001 for ALS in Australia. This liquid form addresses swallowing difficulties common in ALS patients. NUZ-001 aims to restore autophagy, ...
I credit Jeff fully with the vigor and zest with which we lived after his diagnosis. He was a decisive man, and had built a ...
An experimental RNA-based therapy shows promise for ALS by preventing TDP-43 protein clumping. An international team of scientists has developed an RNA-based experimental medicine that has the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results